Primary Care Clinics in Richburg, SC Accepting Medicare
5 Primary Care Clinics found. Showing 1 - 5
 Lewisville Medical Center Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 3248 Edgeland Hwy, Richburg, SC 29729 Phone: 803-789-6111 Fax: 803-789-6118 |
Catawba Family Medicine Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3909 Lancaster Hwy, Richburg, SC 29729 Phone: 803-789-5221 |
Medical University Hospital Authority Family Medicine Medicare: Medicare Enrolled Practice Location: 3909 Lancaster Hwy, Richburg, SC 29729 Phone: 803-789-5221 |
Lewisville Medical Center Incorporated Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3248 Edgeland Hwy, Richburg, SC 29729 Phone: 803-789-6111 Fax: 803-789-6118 |
Lewisville Medical Center Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 3248 Edgeland Hwy, Richburg, SC 29729 Phone: 803-789-6111 Fax: 803-789-6118 |
News Archive
Stempeutics' Stempeucel drug receives ATMP classification from EMA for treatment of TAO
Stempeutics Research, a group company of Manipal Education and Medical Group and a Joint Venture with Cipla Group, announced today that the European Medicines Agency has granted Advanced Therapy Medicinal Product classification for its novel stem cell drug 'Stempeucel' which will be used for the treatment of Thromboangiitis Obliterans (TAO).
New study finds 35% of imaging costs ordered for defensive purposes in Pennsylvania
Nearly 35 percent of all the imaging costs ordered for 2,068 orthopaedic patient encounters in Pennsylvania were ordered for defensive purposes, according to a new study presented today at the 2011 Annual Meeting of the American Academy of Orthopaedic Surgeons.
FDA issues Complete Response Letter for approval of Eisai's rabeprazole sodium extended-release capsules
Eisai announced today that the company received a Complete Response Letter from the United States Food and Drug Administration (FDA) regarding the New Drug Application (NDA) of rabeprazole sodium extended-release capsules, 50 mg, an investigational proton pump inhibitor (PPI) under review for the healing and long-term maintenance of healing and symptom resolution of erosive gastroesophageal reflux disease (GERD), and for the treatment of daytime and nighttime heartburn and other symptoms of non-erosive GERD.
Study: Near-normal glucose control does not delay risk of organ damage in diabetes patients
In people with longstanding type 2 diabetes who are at high risk for heart attack and stroke, lowering blood sugar to near-normal levels did not delay the combined risk of diabetic damage to kidneys, eyes, or nerves, but did delay several other signs of diabetic damage, a study has found. The intensive glucose treatment was compared with standard glucose control.
› Verified 7 days ago